No Eye Should Stay Dry. Dry Eye Disease: More Than Just Discomfort

Dry Eye Disease: More Than Just Discomfort

Dry eye is not just an irritation. It is a signal.
And no eye should stay dry.

Dry Eye Disease (DED) is one of the most common ocular conditions worldwide, affecting millions of people every day. Yet despite its prevalence, it is still widely misunderstood, underdiagnosed, and often treated by trial and error. What patients call “dryness” is rarely just dryness. It is a complex, multifactorial disease that can quietly undermine vision, comfort, and quality of life.

What Is Dry Eye Disease?

Dry Eye Disease occurs when the tear film fails to do its job. To protect, nourish, and stabilize the ocular surface. This failure may result from insufficient tear production, excessive evaporation, or poor tear quality.

The tear film is not simply water. It is a sophisticated biological system made of lipids, aqueous fluid, and proteins, working in precise balance. When that balance breaks down, the ocular surface becomes exposed, inflamed, and vulnerable.

The Symptoms Patients Feel, and the Signs We Often Miss

Dry eye presents differently in every patient. Symptoms can be persistent, fluctuating, or seemingly contradictory. Common complaints include:

  • Burning or stinging sensations

  • Grittiness or foreign body feeling

  • Redness and irritation

  • Blurred or fluctuating vision

  • Light sensitivity

  • Excessive tearing, paradoxically triggered by surface irritation

Because symptoms are subjective and inconsistent, relying on how the patient feels is often not enough. What the eye experiences and what the eye reveals are not always the same.

Why Dry Eye Is So Hard to Diagnose

Dry eye is not one disease. It is a spectrum.

Underlying mechanisms may include aqueous tear deficiency, evaporative dry eye, inflammatory processes, or allergic and mixed etiologies. Traditional diagnostic approaches depend heavily on patient questionnaires and slit lamp examination, which can miss early disease or fail to identify the dominant driver.

That is why objective, point of care diagnostics are no longer optional. They are essential.

Objective diagnostics help clinicians:

  • Differentiate between dry eye subtypes

  • Detect disease earlier

  • Monitor progression over time

  • Measure response to treatment

  • Make confident, evidence-based decisions

Inflammation: The Missing Piece

In many patients, inflammation is the silent engine driving dry eye. Changes in tear composition, including shifts in protein levels, reflect underlying biological activity on the ocular surface long before damage becomes visible.

Understanding what is happening in the tear film itself provides a window into the real state of the eye. Beyond what symptoms suggest. Beyond what the slit lamp can show.

Why Early and Accurate Diagnosis Changes Everything

When dry eye is missed or mismanaged, the consequences extend far beyond discomfort. Chronic inflammation can impair visual performance, compromise the ocular surface, reduce tolerance to contact lenses, and complicate surgical outcomes.

Early, accurate diagnosis allows clinicians to intervene sooner, personalize treatment, and improve long-term outcomes. For patients, it means relief that lasts. For clinicians, it means clarity.

Looking Ahead: A Smarter Future for Dry Eye Care

The future of dry eye management is not guesswork. It is precision.

By combining clinical expertise with rapid, objective tear-based diagnostics, clinicians can move from symptom chasing to true disease understanding. When we measure what matters, we treat what matters.

Better diagnostics lead to better decisions.
And better decisions lead to healthier eyes.

No eye should stay dry.

contact us

Phone: 073-2753400
Email: [email protected]

Prof. Leonard Bielory

  • Professor of Medicine, Allergy, Immunology, and Ophthalmology
  • Top expert in the diagnosis and treatment of allergic conjunctivitis and ocular allergies
  • Ex – Director of the Allergy and Immunology Section at Rutgers University
  • Has authored over 200 peer-reviewed publications

Brian Smith

  • General Manager, eye Health at Quidel-Ortho
  • Ex- Surgical Account Consultant Surgical Account Consultant and area manager at Allergan
  • Ex – Cataract Account Manager at Alcon
  • Ex – Teaching Institute Manager/Refractive Implant Specialist at Abbott

Dr. Ron Neumann

  • CMO of BioLight
  • Expert ophthalmologist, specializing in inflammatory eye diseases
  • Senior consultant to Maccabi HMO
  • Former Global Medical Director for innovative Products – TEVA
  • Co chairman – ISOPT
  • Founder – FOIS

Prof. David Zadok

Director

  • Director of Ophthalmology at Shaare Zedek MC, Jerusalem. 
  • Former Chairperson OIS
  • Former Head of the Israel Cornea Society 
  • Fellowship in Corneal Diseases UCSD, San Diego
  • Co-authored over 70 scientific publications, 2 book chapters
  • Member of AAO, Asia Cornea Society and Israeli Society of Vision and Eye Research

John Sinclair

Director

Mr. Sinclair is a Canadian CPA with extensive experience in the field of finance, accounting and the audit of public companies. With a career spanning several decades, he has served as Senior Partner with various audit firms including Smith, Nixon LLP, Collins Barrow Toronto LLP and Baker Tilly WM LLP, including as Managing Partner of Baker Tilly WM LLP’s Toronto office. During these tenures, Sinclair played a pivotal role in initiating and driving growth, managing complex projects, and providing financial advisory services to clients around the world. Mr. Sinclair is currently a director of Lifeist Wellness Inc. (“Lifeist”), a company listed on the TSX Venture Exchange, where he also serves as the chair of the Lifeist audit committee. Mr. Sinclair graduated from the University of Toronto with a Bachelor of Arts, Commerce and Economics, in April 1983.

Igal Kohn

Director

Igal Kohn is currently, and has been since January 2017, the CEO of Elcam. Mr. Kohn has been with Elcam for over 25 years, starting in January 1998 as the CFO. Mr. Kohn holds an Israeli CPA certification. As the CFO of Elcam, Mr. Kohn was responsible for overseeing all mergers and acquisitions activities, managing the Elcam’s subsidiaries and handling all financial and legal matters. Mr. Kohn’s extensive experience in financial management and strategic operations positioned him to lead Elcam as CEO.

Karin Gurevitz

Director

Karin Gurevitz has served as BioLight Vice President, BioLight Group General Counsel and Company Secretary since 2015. Ms. Gurevitz is a veteran legal advisor with 25 years of experience in legal and compliance management in global public and private companies in various fields. Ms. Gurevitz holds an LL.B. and an MBA from Tel Aviv University, Israel and is a member of the Israel Bar Association.

Julia Reznick Zilberman

Director

Julia Reznick Zilberman has been serving as VP of Business Development at Psifas (National Initiative for Precision Medicine) since May 2024. Before joining Psifas, Ms. Reznick Zilberman led strategic initiatives 96 at a company developing AI solutions for drug development (January 2023 to February 2024) and served as VP of Finance (CFO) and Business Development at an innovative ophthalmology startup (January 2018 to January 2023), which successfully completed several funding rounds. Prior to that, Ms. Reznick worked for 18 years at Teva Pharmaceutical Industries, where she held various senior finance and commercial roles, including managing financial strategy and operations. Ms. Reznick Zilberman also consults for startup companies, providing her expertise in business development and financial strategy. Ms. Reznick Zilberman holds an MBA in Finance and Information Systems, as well as a bachelor’s degree in Economics and Management, both from Tel Aviv University.

Yifftach Biel

Chief Financial Officer

  • CFO – BioLight (TASE:BOLT)
  • Ex BioLight corporate controller
  • Ex Delek Global Real Estate (AIM:DGRE)
  • Certified CPA

Dr. Amos Sommer

VP Technology

  • Almost 3 decades experience in IVD R&D
  • World expert in developing lateral-flow rapid tests
  • Developed the HIV rapid test line for Alere (now Abbott)
  • Developed the TeaRx core platform and DES test

Dr. Shimon Gross

Chief Executive Officer

  • >20 years experience in IVD
  • Ex VP Genomics division– AID Genomics 
  • Ex VP Sales & Marketing  – Savyon Diagnostics
  • >25 peer-reviewed publications and patents

Yaacov Michlin

Chairman of the Board

Yaacov Michlin has served as CEO of Biolight since April 2020. Before joining Biolight, Mr. Michlin managed a medical device company selling mainly in U.S. and led such company’s initial public offering on the NASDAQ. Mr. Michlin currently serves on various boards of directors in the portfolio of Biolight and is leading the life sciences activities in IATI (umbrella organization of the Israeli high-tech sector). Mr. Michlin is also the chairman of MIXIII Health Tech IL, a major conference in Israel. Mr. Michlin has an MBA from the Technion, cum laude, LLM and LLB and BSC in Economics, cum laude, Bar Ilan University.